Cencora | Pharma solutions reported new late-stage clinical data showing an mRNA-based personalized cancer therapy delivering improved outcomes in combination with established immunotherapy.
Published
Signal category
Research & Knowledge
Quote
“New late-stage clinical data showed an mRNA-based personalized cancer therapy delivering meaningfully improved outcomes in combination with established immunotherapy.”
— Eric Monzon|Cencora | Pharma solutions team
Company
Cencora | Pharma solutions
At Cencora, we are investing and innovating alongside our pharma customers to unlock their product’s potential.
- Industry
- Pharmaceutical Manufacturing
- Location
- Conshohocken, US
- Company size
- 2,458 employees
At Cencora, we are investing and innovating alongside our pharma customers to unlock their product’s potential. Cencora is a leading global pharmaceutical solutions organization centered on improving lives. We partner with pharmaceutical innovators and care providers to facilitate access to pharmaceuticals and healthcare products. Our pharma solutions — ranging from support during drug discovery to lifecycle management — help pharmaceutical and biopharma companies of all sizes reach full product potential. Previously known as AmerisourceBergen, our 46,000+ Cencora team members power our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #11 on the Fortune 500 and #21 on the Global Fortune 500 with more than $200 billion in annual revenue. Learn more at www.Cencora.com.